Novo Nordisk Outlines Likely COVID-19 Crisis Trial Impacts

Group Heralds Semaglutide’s Positive Phase II NASH Outcome

 
• By Sten Stovall
  
Novo_Nordisk
GLP-1 semaglutide met its primary endpoint in the Phase II proof-of-concept study • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D